Curis (CRIS) Competitors $4.18 -0.10 (-2.34%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CRIS vs. XFOR, NTGN, CDTX, RGLS, AGEN, FBIO, SABS, BOLT, MTEM, and AMGNShould you be buying Curis stock or one of its competitors? The main competitors of Curis include X4 Pharmaceuticals (XFOR), Neon Therapeutics (NTGN), Cidara Therapeutics (CDTX), Regulus Therapeutics (RGLS), Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), and Amgen (AMGN). These companies are all part of the "medical" sector. Curis vs. X4 Pharmaceuticals Neon Therapeutics Cidara Therapeutics Regulus Therapeutics Agenus Fortress Biotech SAB Biotherapeutics Bolt Biotherapeutics Molecular Templates Amgen Curis (NASDAQ:CRIS) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Does the media favor CRIS or XFOR? In the previous week, Curis had 3 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 5 mentions for Curis and 2 mentions for X4 Pharmaceuticals. Curis' average media sentiment score of 0.23 beat X4 Pharmaceuticals' score of 0.00 indicating that Curis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Curis 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CRIS or XFOR more profitable? X4 Pharmaceuticals has a net margin of 0.00% compared to Curis' net margin of -468.18%. X4 Pharmaceuticals' return on equity of -163.17% beat Curis' return on equity.Company Net Margins Return on Equity Return on Assets Curis-468.18% -327.92% -68.03% X4 Pharmaceuticals N/A -163.17%-54.32% Do analysts rate CRIS or XFOR? Curis presently has a consensus price target of $23.00, suggesting a potential upside of 450.24%. X4 Pharmaceuticals has a consensus price target of $3.67, suggesting a potential upside of 606.49%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Curis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00X4 Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more volatility & risk, CRIS or XFOR? Curis has a beta of 3.32, indicating that its stock price is 232% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Do insiders and institutionals have more ownership in CRIS or XFOR? 30.0% of Curis shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 5.7% of Curis shares are owned by company insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, CRIS or XFOR? Curis has higher revenue and earnings than X4 Pharmaceuticals. Curis is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCuris$10.02M2.49-$47.41M-$8.24-0.51X4 Pharmaceuticals$563K155.33-$101.17M$0.086.49 Does the MarketBeat Community favor CRIS or XFOR? Curis received 618 more outperform votes than X4 Pharmaceuticals when rated by MarketBeat users. Likewise, 67.75% of users gave Curis an outperform vote while only 66.36% of users gave X4 Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCurisOutperform Votes69167.75% Underperform Votes32932.25% X4 PharmaceuticalsOutperform Votes7366.36% Underperform Votes3733.64% SummaryCuris beats X4 Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.00M$3.15B$5.54B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-0.5111.73114.8115.14Price / Sales2.49397.851,495.55100.10Price / CashN/A148.6639.6734.08Price / Book1.254.024.665.02Net Income-$47.41M-$42.25M$119.06M$225.46M7 Day Performance-16.23%8.04%0.80%0.37%1 Month Performance-18.68%8.69%5.65%3.57%1 Year Performance-7.32%32.09%36.75%29.43% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris3.0834 of 5 stars$4.18-2.3%$23.00+450.2%-11.3%$25.00M$10.02M-0.5149Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageXFORX4 Pharmaceuticals4.3077 of 5 stars$0.52+4.0%$3.67+606.5%-30.9%$87.45M$563,000.006.4980News CoverageNTGNNeon TherapeuticsN/A$3.07flatN/AN/A$88.93MN/A-1.15102CDTXCidara Therapeutics4.3655 of 5 stars$13.09+0.7%$29.67+126.6%-18.5%$92.13M$53.87M-0.5390Upcoming EarningsNews CoverageRGLSRegulus Therapeutics2.7068 of 5 stars$1.49+2.1%$10.80+624.8%+21.1%$97.55MN/A-1.1830Analyst ForecastNews CoverageGap UpAGENAgenus3.8171 of 5 stars$4.05-3.6%$10.50+159.3%-75.6%$87.36M$156.31M-0.36389Upcoming EarningsShort Interest ↑FBIOFortress Biotech2.8545 of 5 stars$1.90flat$13.00+584.2%+13.1%$43.34M$84.51M-0.59186High Trading VolumeSABSSAB Biotherapeutics2.6412 of 5 stars$3.88+19.0%$12.40+219.6%+288.0%$35.81M$2.24M0.00140Negative NewsHigh Trading VolumeBOLTBolt Biotherapeutics2.703 of 5 stars$0.66+3.1%$3.50+431.5%-33.2%$25.20M$11.17M-0.38100Gap UpMTEMMolecular Templates1.6746 of 5 stars$0.46+2.2%N/A-90.8%$2.96M$57.31M-0.1762Negative NewsAMGNAmgen4.5954 of 5 stars$319.22-0.3%$333.50+4.5%+22.4%$171.53B$28.19B40.8726,700Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies X4 Pharmaceuticals Competitors Neon Therapeutics Competitors Cidara Therapeutics Competitors Regulus Therapeutics Competitors Agenus Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRIS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
